Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.05 -1.2%	$4.11	$1.80 ▼ $20.83	$17.41M	-0.85	1.10 million shs	45,701 shs
GHSI Guardion Health Sciences	$3.22 -2.1%	$3.24	$3.04 ▼ $18.00	$4.35M	0.73	105,261 shs	4,700 shs
HOTH Hoth Therapeutics	$1.13 -3.4%	$1.02	$0.58 ▼ $3.80	$15.45M	0.55	3.71 million shs	429,679 shs
LPCN Lipocine	$3.29 +2.2%	$3.30	$2.68 ▼ $8.71	$17.23M	1.34	32,934 shs	34,791 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	-1.22%	-2.17%	+1.25%	-6.90%	+618.09%
GHSI Guardion Health Sciences	0.00%	0.00%	0.00%	0.00%	-67.37%
HOTH Hoth Therapeutics	-3.42%	-6.61%	+33.36%	+9.71%	+22.83%
LPCN Lipocine	+2.17%	-0.30%	-3.24%	+0.30%	-58.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CING Cingulate	3.0974 of 5 stars	3.5	4.0	0.0	0.0	3.6	0.8	0.6
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	2.0013 of 5 stars	3.6	2.0	0.0	0.0	2.3	0.0	0.6
LPCN Lipocine	2.2448 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	3.00	Buy	$26.00	541.98% Upside
GHSI Guardion Health Sciences	0.00	N/A	N/A	N/A
HOTH Hoth Therapeutics	3.25	Buy	$4.00	253.98% Upside
LPCN Lipocine	3.00	Buy	$9.00	173.56% Upside

Current Analyst Ratings Breakdown

Latest GHSI, CING, LPCN, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00
5/19/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
4/21/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
GHSI Guardion Health Sciences	$12.25M	0.35	$0.14 per share	23.15	$6.39 per share	0.50
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
LPCN Lipocine	$11.20M	1.57	N/A	N/A	$3.93 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$15.55M	-$8.48	N/A	N/A	N/A	N/A	-229.78%	-142.28%	8/12/2025 (Estimated)
GHSI Guardion Health Sciences	$160K	$4.87	0.66	∞	N/A	22.79%	-73.69%	-48.17%	N/A
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)

Latest GHSI, CING, LPCN, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/8/2025	Q1 2025	CING Cingulate	-$1.00	-$1.04	-$0.04	-$1.04	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
GHSI Guardion Health Sciences	$5.00	155.28%	N/A	102.67%	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	0.16	1.87	1.87
GHSI Guardion Health Sciences	N/A	16.68	16.59
HOTH Hoth Therapeutics	N/A	15.09	15.08
LPCN Lipocine	N/A	15.64	15.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
GHSI Guardion Health Sciences	20.21%
HOTH Hoth Therapeutics	7.08%
LPCN Lipocine	9.11%

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.27%
GHSI Guardion Health Sciences	1.32%
HOTH Hoth Therapeutics	6.92%
LPCN Lipocine	6.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	20	4.25 million	4.02 million	Not Optionable
GHSI Guardion Health Sciences	10	1.35 million	1.33 million	Not Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
LPCN Lipocine	10	5.35 million	5.01 million	No Data

GHSI, CING, LPCN, and HOTH Headlines

Recent News About These Companies

Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154

June 27 at 6:06 PM | msn.com

Lipocine (NASDAQ:LPCN) Share Price Crosses Below 200 Day Moving Average - Here's Why

June 27 at 4:23 AM | americanbankingnews.com

Lipocine Begins Phase 3 Trial for LPCN 1154

June 26 at 10:11 AM | tipranks.com

Lipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

June 26 at 9:45 AM | finanznachrichten.de

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

June 26 at 8:00 AM | prnewswire.com

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

June 23, 2025 | prnewswire.com

Le partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oral

June 9, 2025 | fr.investing.com

Lipocine annonce le dépôt d'une demande d'autorisation de mise sur le marché pour TLANDO au Canada

June 9, 2025 | zonebourse.comZ

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

June 9, 2025 | prnewswire.com

Le LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de Hepatology

May 23, 2025 | zonebourse.comZ

Lipocine’s LPCN 1148 Gains Fast Track Designation

May 22, 2025 | tipranks.com

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025 | prnewswire.com

Lipocine to Present at A.G.P. Healthcare Showcase

May 14, 2025 | tipranks.com

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025 | prnewswire.com

Lipocine Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025 | prnewswire.com

Lipocine inks license and supply agreement for TLANDO in Brazil

May 7, 2025 | msn.com

Lipocine s’associe à Aché pour commercialiser TLANDO au Brésil

May 7, 2025 | fr.investing.com

Lipocine Inc. annonce un accord de licence et d'approvisionnement pour Tlando® au Brésil

May 7, 2025 | zonebourse.comZ

Lipocine Partners with Aché for TLANDO® in Brazil

May 6, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Hims & Hers Stock: Buy the Dip or Wait It Out?
By Gabriel Osorio-Mazilli | June 5, 2025
View Hims & Hers Stock: Buy the Dip or Wait It Out?
Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
By Jeffrey Neal Johnson | June 8, 2025
View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes
By Gabriel Osorio-Mazilli | June 9, 2025
View Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes

GHSI, CING, LPCN, and HOTH Company Descriptions

Cingulate NASDAQ:CING

$4.05 -0.05 (-1.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.06 +0.00 (+0.12%)

As of 06/27/2025 07:58 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Hoth Therapeutics NASDAQ:HOTH

$1.13 -0.04 (-3.42%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 06/27/2025 07:53 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Lipocine NASDAQ:LPCN

$3.29 +0.07 (+2.17%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.33 +0.04 (+1.25%)

As of 06/27/2025 07:58 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time